Business
CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team
Dr. Kelley adds two decades of highly relevant drug development and regulatory strategy experience spanning oncology, rare diseases and CNS Newly formed executive team is committed to execution and company evolution focused on patient and stakeholder ...
About this update from Cns Pharmaceuticals, Inc.
[{"type":"text","content":"Dr. Kelley adds two decades of highly relevant drug development and regulatory strategy experience spanning oncology, rare diseases and CNS","length":139,"tagName":"p"},{"type":"text","content":"Newly formed executive team is committed to execution and company evolution focused on patient and stakeholder value","length":116,"tagName":"p"},{"type":"text","content":"HOUSTON, TX / ACCESS Newswire / March 2, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the appointment of Lynne Kelley, MD, FACS, as Chief Medical Officer.","length":374,"tagName":"p"},{"type":"text","content":"Dr. Kelley brings more than two decades of global leadership experience across clinical development, translational medicine and regulatory strategy in oncology, rare diseases, CNS and medical devices. She has successfully led Phase 1-3 clinical programs and supported regulatory approvals across the United States, Europe, China, and Japan, and is widely recognized for building high-performing medical organizations and delivering successful regulatory and commercial outcomes.","length":478,"tagName":"p"},{"type":"text","content":""The depth, breadth and experience that Dr. Kelley brings to the Company will be instrumental as we prioritize and strategically build our pipeline. She is an exceptional medical leader with deep expertise in oncology, CNS and rare disease drug development and will play a key role in driving the Company forward, creating meaningful advancements for patients and significant value for our shareholders," said Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals.","length":493,"tagName":"p"},{"type":"text","content":"Prior to joining CNS Pharmaceuticals, Dr. Kelley served as Chief Medical Officer at multiple public and private biotechnology and medical device companies, including TISSIUM, Servier Pharmaceuticals, X4 Pharmaceuticals and Senseonics. She has led clinical development programs resulting in INDs, NDAs, BLAs, PMAs, and breakthrough and orphan drug designations, and has global regulatory experience designing clinical trials as well as interactions with FDA advisory committees that resulted...